Related Experiment Video

Updated: Aug 19, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?

Animesh Dhar1, Smita Mehta, Snigdha Banerjee

  • 1Cancer Research Unit, Department of Veterans Affairs Medical Center, 4801 East Linwood Boulevard, Kansas City, MO 64128-2226, USA. Animesh.Dhar@med.va.gov <Animesh.Dhar@med.va.gov>

Frontiers in Bioscience : a Journal and Virtual Library
|March 17, 2005
PubMed

Insights

Targeting epidermal growth factor receptors (EGFR) offers a promising pancreatic cancer therapy. Gene silencing and blocking EGFR show potential for treating pancreatic adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) expression is elevated in pancreatic adenocarcinoma.
  • EGFR activation plays a key role in the growth and differentiation of pancreatic cancer and other tumors.

Purpose of the Study:

  • To explore the potential of targeting EGFR as an anti-cancer therapy for pancreatic adenocarcinoma.
  • To investigate the efficacy of blocking or inactivating EGFR using monoclonal antibodies or tyrosine kinase inhibitors.
  • To evaluate the use of antisense or gene silencing of EGFR in pancreatic cancer cells as a novel targeted therapy.

Main Methods:

  • Utilizing monoclonal antibodies to block EGFR.
  • Employing tyrosine kinase inhibitors to inactivate EGFR.
  • Implementing antisense technology and gene silencing techniques for EGFR in pancreatic cancer cells.

Main Results:

  • EGFR blockade and inactivation demonstrate significant potential as anti-cancer strategies.
  • Antisense and gene silencing of EGFR represent recent advancements in targeted pancreatic cancer therapy.

Conclusions:

  • Targeting EGFR, through blockade or gene silencing, holds considerable promise for treating pancreatic adenocarcinoma.
  • Further research into these molecular biology approaches could lead to effective new treatments for pancreatic cancer patients.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...